---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 160
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the txgnn-pipeline skill context, I'll now generate the full evaluation report for this Evidence Pack.

---

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody targeting the RSV (Respiratory Syncytial Virus) F protein, used for RSV prophylaxis in high-risk infants and young children.
The TxGNN model predicts it may be effective for **Benign Neoplasm of Tongue**, however there are **0 clinical trials** and **0 publications** currently supporting this direction.
This prediction is assessed as a knowledge graph artifact with no mechanistic basis, and is not recommended for further development.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | RSV prophylaxis in high-risk pediatric patients |
| Predicted New Indication | Benign Neoplasm of Tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Italy Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

It is not. This section explains why the TxGNN score is high despite the absence of any real biological connection.

Palivizumab is a humanized monoclonal antibody (IgG1κ) that binds to the fusion (F) protein of Respiratory Syncytial Virus (RSV), blocking viral entry into host respiratory epithelial cells. Its mechanism is purely antiviral and entirely specific to RSV. There is no known or hypothesized anti-proliferative, anti-tumor, or immunomodulatory activity relevant to neoplastic tissue.

Benign neoplasm of the tongue (e.g., fibroma, papilloma) arises from local trauma, HPV infection, or developmental factors. RSV has no established oncogenic potential and does not infect oral or oropharyngeal mucosa as a primary target. There are no published data — not even case reports — linking RSV infection or Palivizumab exposure to any tongue neoplasm outcome.

The most likely explanation for the high TxGNN score is a **knowledge graph shared-node artifact**: Palivizumab is registered as a pediatric drug in multiple KG datasets, and many of the predicted indications (benign neoplasms, neuroblastoma, thyroglossal duct cyst) are also pediatric-prevalent conditions. The model captures this co-occurrence as a disease–drug association signal, but the signal reflects demographic co-occurrence, not pharmacological mechanism. All 10 top-ranked predicted indications follow this same pattern and all carry a "Hold" recommendation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All TxGNN predicted indications for Palivizumab are neoplastic or developmental conditions with no mechanistic connection to anti-RSV activity; the high prediction scores are consistent with a knowledge graph demographic co-occurrence artifact rather than any pharmacological signal. There is zero supporting clinical or preclinical evidence across all 10 ranked indications.

**To proceed, the following is needed:**

- Mechanistic reassessment: If future research identifies an immune-modulatory or anti-tumor activity for anti-RSV monoclonal antibodies (e.g., off-target innate immune activation), the evidence base should be re-evaluated.
- KG model audit: The shared-node artifact pattern seen across all 10 predictions should be reported back to the TxGNN modelling team for graph edge re-weighting or demographic feature deconfounding.
- Do not initiate any preclinical or clinical repurposing work for any of the 10 predicted indications at this time.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

